KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2025)

Amneal Pharmaceuticals has reported Invested Capital over the past 9 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly results put Invested Capital at $2.5 billion for Q4 2025, up 5186.91% from a year ago — trailing twelve months through Dec 2025 was $2.5 billion (up 5186.91% YoY), and the annual figure for FY2025 was $2.5 billion, up 5186.91%.
  • Invested Capital for Q4 2025 was $2.5 billion at Amneal Pharmaceuticals, up from $2.5 billion in the prior quarter.
  • Over the last five years, Invested Capital for AMRX hit a ceiling of $2.8 billion in Q3 2022 and a floor of -$49.2 million in Q4 2024.
  • Median Invested Capital over the past 5 years was $2.3 billion (2024), compared with a mean of $1.9 billion.
  • Biggest five-year swings in Invested Capital: plummeted 102.01% in 2024 and later skyrocketed 5186.91% in 2025.
  • Amneal Pharmaceuticals' Invested Capital stood at $430.3 million in 2021, then surged by 552.05% to $2.8 billion in 2022, then dropped by 13.04% to $2.4 billion in 2023, then plummeted by 102.01% to -$49.2 million in 2024, then skyrocketed by 5186.91% to $2.5 billion in 2025.
  • The last three reported values for Invested Capital were $2.5 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.1 billion (Q2 2025) per Business Quant data.